$XWEL
XWELL Inc Stock $xwel

$xwel Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000155837022004897 Filed on March 31, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$29.36M	$73.73M	$320.0K
YoY Change	9074.38%	779.3%	-97.05%
Cost Of Revenue	$15.86M	$41.39M	$2.430M
YoY Change	552.8%	245.36%	-73.62%
Gross Profit	$13.50M	$32.34M	-$2.110M
YoY Change	-739.57%	-998.94%	-229.45%
Gross Profit Margin	45.97%	43.87%	-659.38%
Selling, General & Admin	$9.849M	$24.20M	$4.970M
YoY Change	98.17%	51.81%	-2.93%
% of Gross Profit	72.98%	74.82%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$659.0K	$3.201M	$1.330M
YoY Change	-50.45%	-38.56%	-6.99%
% of Gross Profit	4.88%	9.9%
Operating Expenses	$10.51M	$24.20M	$6.300M
YoY Change	66.79%	51.81%	-3.82%
Operating Profit	$2.987M	$4.107M	-$8.410M
YoY Change	-135.52%	-110.24%	70.93%
Interest Expense	-$317.0K	-$1.002M	$20.00K
YoY Change	-1685.0%	-45.25%	-102.35%
% of Operating Profit	-10.61%	-24.4%
Other Income/Expense, Net	-$42.00K	-$1.201M	$1.250M
YoY Change	-103.36%	-239.98%	-54.71%
Pretax Income	$1.813M	$2.949M	-$16.41M
YoY Change	-111.05%	-103.2%	134.43%
Income Tax	-$23.00K	$56.00K	-$20.00K
% Of Pretax Income	-1.27%	1.9%
Net Earnings	$3.275M	$3.349M	-$15.68M
YoY Change	-120.89%	-103.7%	121.78%
Net Earnings / Revenue	11.16%	4.54%	-4900.0%
Basic Earnings Per Share		$0.03
Diluted Earnings Per Share	$30.49K	$0.03	-$216.8K
COMMON SHARES
Basic Shares Outstanding	105.7M	104.3M
Diluted Shares Outstanding		105.1M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$105.5M	$105.5M	$89.80M
YoY Change	17.49%	17.49%	3981.82%
Cash & Equivalents	$105.5M	$105.5M	$89.80M
Short-Term Investments
Other Short-Term Assets	$1.095M	$1.095M	$1.321M
YoY Change	-17.11%	-15.77%	20.09%
Inventory	$1.763M	$1.763M	$657.0K
Prepaid Expenses	$1.047M		$1.135M
Receivables	$615.0K	$615.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$109.0M	$109.0M	$91.78M
YoY Change	18.74%	18.71%	2253.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.658M	$10.99M	$4.161M
YoY Change	60.01%	52.69%	-74.47%
Goodwill
YoY Change
Intangibles	$3.732M		$870.0K
YoY Change	328.97%
Long-Term Investments
YoY Change
Other Assets	$2.810M	$3.561M	$2.588M
YoY Change	8.58%	7.91%	52.24%
Total Long-Term Assets	$18.29M	$18.29M	$11.35M
YoY Change	61.06%	61.83%	-54.22%
TOTAL ASSETS
Total Short-Term Assets	$109.0M	$109.0M	$91.78M
Total Long-Term Assets	$18.29M	$18.29M	$11.35M
Total Assets	$127.3M	$127.3M	$103.1M
YoY Change	23.4%	23.44%	259.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.535M	$13.00M	$7.400M
YoY Change	-25.2%	75.68%	-41.27%
Accrued Expenses	$2.736M	$2.736M	$2.800M
YoY Change	-2.29%	-2.29%	-24.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.584M	$3.584M	$3.300M
YoY Change	8.61%	8.61%
Total Short-Term Liabilities	$19.83M	$19.83M	$13.48M
YoY Change	47.12%	46.87%	-16.81%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$2.400M
YoY Change	-100.0%	-100.0%	-58.62%
Other Long-Term Liabilities	$7.504M	$7.504M	$6.900M
YoY Change	8.75%	8.75%	-25.81%
Total Long-Term Liabilities	$7.504M	$7.504M	$9.300M
YoY Change	-19.31%	-19.31%	-38.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.83M	$19.83M	$13.48M
Total Long-Term Liabilities	$7.504M	$7.504M	$9.300M
Total Liabilities	$27.33M	$34.53M	$22.76M
YoY Change	20.07%	36.5%	-34.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$395.3M		-$398.6M
YoY Change	-0.84%
Common Stock	$1.013M		$941.0K
YoY Change	7.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$92.73M	$92.73M	$77.81M
YoY Change
Total Liabilities & Shareholders Equity	$127.3M	$127.3M	$103.1M
YoY Change	23.4%	23.44%	259.35%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	$3.275M	$3.349M	-$15.68M
YoY Change	-120.89%	-103.7%	121.78%
Depreciation, Depletion And Amortization	$659.0K	$3.201M	$1.330M
YoY Change	-50.45%	-38.56%	-6.99%
Cash From Operating Activities	$8.594M	$14.56M	-$8.080M
YoY Change	-206.36%	-158.22%	-1305.97%
INVESTING ACTIVITIES
Capital Expenditures	-$2.784M	$4.282M	-$870.0K
YoY Change	220.0%	7.89%	35.94%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$2.434M
YoY Change
Cash From Investing Activities	-$2.784M	-$5.156M	-$870.0K
YoY Change	220.0%	18.56%	35.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$7.825M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-9.429M	6.350M	36.87M
YoY Change	-125.57%	-94.58%	-10341.67%
NET CHANGE
Cash From Operating Activities	8.594M	14.56M	-8.080M
Cash From Investing Activities	-2.784M	-5.156M	-870.0K
Cash From Financing Activities	-9.429M	6.350M	36.87M
Net Change In Cash	-3.619M	15.76M	27.92M
YoY Change	-112.96%	-82.07%	-8560.61%
FREE CASH FLOW
Cash From Operating Activities	$8.594M	$14.56M	-$8.080M
Capital Expenditures	-$2.784M	$4.282M	-$870.0K
Free Cash Flow	$11.38M	$10.28M	-$7.210M
YoY Change	-257.81%	-135.47%	-650.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.05
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001410428
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94058853
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101269349
CY2020Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.33
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2588000
CY2021	dei	Auditor Location AuditorLocation	East Hanover, New Jersey
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	105506000
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-34785
CY2021	dei	Entity Registrant Name EntityRegistrantName	XpresSpa Group, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4988129
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	254 West 31st Street
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	11th Floor
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10001
CY2021	dei	City Area Code CityAreaCode	(212)
CY2021	dei	Local Phone Number LocalPhoneNumber	309-7549
CY2021	dei	Security12b Title Security12bTitle	Common Stock
CY2021	dei	Trading Symbol TradingSymbol	XSPA
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	162522363
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	95071210
CY2021	dei	Auditor Firm AuditorFirmId	711
CY2021	dei	Auditor Name AuditorName	Friedman LLP
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89801000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	615000
CY2021Q4	us-gaap	Inventory Net InventoryNet	1763000
CY2020Q4	us-gaap	Inventory Net InventoryNet	657000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1095000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1321000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	108979000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	91779000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	751000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	701000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6658000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4161000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3732000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	870000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4336000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3034000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2810000
CY2021Q4	us-gaap	Assets Assets	127266000
CY2020Q4	us-gaap	Assets Assets	103133000
CY2021Q4	xspa	Accounts Payable Accrued Liabilities And Other Current AccountsPayableAccruedLiabilitiesAndOtherCurrent	12958000
CY2020Q4	xspa	Accounts Payable Accrued Liabilities And Other Current AccountsPayableAccruedLiabilitiesAndOtherCurrent	6468000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2736000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2797000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-312000
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	11983000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3201000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5210000
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	837000
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	15356000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24199000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-220000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	92732000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	77806000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	7203000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	2565000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	99935000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	80371000
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	549000
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	914000
CY2021Q4	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	3584000
CY2020Q4	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	3298000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19827000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13477000
CY2020Q4	us-gaap	Unsecured Long Term Debt UnsecuredLongTermDebt	2355000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7504000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6930000
CY2021Q4	us-gaap	Liabilities Liabilities	27331000
CY2020Q4	us-gaap	Liabilities Liabilities	22762000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101269349
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94058853
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1013000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	941000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	487306000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	475709000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-395275000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-398624000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	127266000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103133000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73729000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8385000
CY2021	us-gaap	Cost Direct Labor CostDirectLabor	13421000
CY2020	us-gaap	Cost Direct Labor CostDirectLabor	6290000
CY2021	xspa	Cost Of Occupancy CostOfOccupancy	2505000
CY2020	xspa	Cost Of Occupancy CostOfOccupancy	2809000
CY2021	xspa	Products And Other Operating Costs ProductsAndOtherOperatingCosts	25459000
CY2020	xspa	Products And Other Operating Costs ProductsAndOtherOperatingCosts	2884000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	41385000
CY2020	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	599000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15940000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	69622000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	48489000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	4107000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-40104000
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	43000
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1832000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	3349000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	80371000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	80371000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2856000
CY2021	us-gaap	Profit Loss ProfitLoss	2893000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-92000
CY2021	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	818000
CY2021	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	-502000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-90488000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-92000
CY2021	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	5109000
CY2021	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	7825000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	63000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2801000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-92169000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.05
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104306173
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44567542
CY2021	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1170000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	99935000
CY2021	us-gaap	Profit Loss ProfitLoss	2893000
CY2020	us-gaap	Profit Loss ProfitLoss	-92232000
CY2020	xspa	Fair Value Adjustment Of Warrants And Conversion Options FairValueAdjustmentOfWarrantsAndConversionOptions	51147000
CY2020	xspa	Fair Value Adjustment Of Contingent Consideration FairValueAdjustmentOfContingentConsideration	-315000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105076758
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44567542
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2536000
CY2020	xspa	Stock Issued During Period Value For Repayment Debt And Interest StockIssuedDuringPeriodValueForRepaymentDebtAndInterest	35000
CY2020	xspa	Direct Offerings Of Registered Common Stock Value DirectOfferingsOfRegisteredCommonStockValue	110619000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	135000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1328000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	51147000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	63000
CY2020	us-gaap	Profit Loss ProfitLoss	-92232000
CY2020	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	244000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1201000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	858000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2949000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92225000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	56000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000
CY2021	us-gaap	Profit Loss ProfitLoss	2893000
CY2020	us-gaap	Profit Loss ProfitLoss	-92232000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-456000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1744000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3201000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5210000
CY2021	xspa	Impairment Of Long Lived Assets ImpairmentOfLongLivedAssets	837000
CY2020	xspa	Impairment Of Long Lived Assets ImpairmentOfLongLivedAssets	15356000
CY2020	us-gaap	Accretion Expense AccretionExpense	1125000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1719000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2015000
CY2020	xspa	Issuance Of Shares Of Common Stock For Repayment Of Debt And Interest IssuanceOfSharesOfCommonStockForRepaymentOfDebtAndInterest	497000
CY2020	xspa	Issuance Of Shares Of Preferred Stock For Repayment Of Debt And Interest IssuanceOfSharesOfPreferredStockForRepaymentOfDebtAndInterest	63000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-182000
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	379000
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	135000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	128000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2856000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1328000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1046000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1287000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1106000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1124000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-365000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1251000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	281000
CY2021	xspa	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1211000
CY2020	xspa	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-2904000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6687000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5169000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	14561000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25012000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4282000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3969000
CY2021	xspa	Proceeds From Acquisition Of Variable Interest Entities ProceedsFromAcquisitionOfVariableInterestEntities	2434000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3308000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	380000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5156000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4349000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	17085000
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	110619000
CY2020	xspa	Proceeds From Paycheck Protection Program ProceedsFromPaycheckProtectionProgram	5653000
CY2020	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	500000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000
CY2020	xspa	Proceeds From Funding Advance Net ProceedsFromFundingAdvanceNet	910000
CY2020	xspa	Payments Of Funding Advance Net PaymentsOfFundingAdvanceNet	819000
CY2021	xspa	Repayment Of Paycheck Protection Program RepaymentOfPaycheckProtectionProgram	2069000
CY2021	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	502000
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7825000
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	818000
CY2020	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	599000
CY2021	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	1170000
CY2020	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	244000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6350000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	117225000
CY2020	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	3000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15755000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	87867000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90502000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2635000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106257000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90502000
CY2021	us-gaap	Interest Paid InterestPaid	11000
CY2020	us-gaap	Interest Paid InterestPaid	187000
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	11000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1081000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Note 1. General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">XpresSpa Group, Inc. (“XpresSpa Group”) is a leading global travel health and wellness services holding company. XpresSpa Group currently has three reportable operating segments: XpresSpa, XpresTest, and Treat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">XpresSpa has been a global airport retailer of spa services through its XpresSpa spa locations, offering travelers premium spa services, including massage, nail and skin care, as well as spa and travel products (“XpresSpa”). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Due to the COVID-19 Outbreak, effective March 24, 2020, the Company temporarily closed all global spa locations, largely due to the categorization of our spa locations by local jurisdictions as “non-essential services”. Normal market conditions and travel behavior were negatively impacted by the COVID-19 outbreak. Similar to many businesses in the travel sector, the Company’s business has been materially and adversely impacted by the COVID-19 outbreak. Most of the domestic travel restrictions have been lifted as of December 31, 2021 and the Company believes that travel conditions are slowly returning to normal. The Company has reopened sixteen locations out of its total domestic portfolio of 31 Spas. As travel slowly returns, the Company’s intention is to continue to review its portfolio and reopen spas once airport traffic returns to sufficient levels to support its operations and achieve adequate unit-level economics, including acceptable profit levels as well as serves our longer-term strategy of offering fully integrated health and wellness services.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:8pt;text-decoration-color:#000000;visibility:hidden;"></span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Since the beginning of the temporary closure of XpresSpa locations, the Company through XpresSpa Group’s subsidiary XpresTest, Inc. (“XpresTest”), launched XpresCheck Wellness Centers, also in airports. XpresCheck offers COVID-19 and other medical diagnostic testing services to the traveling public, as well as airline, airport and concessionaire employees, and TSA and U.S. Customs and Border Protection agents. XpresTest has entered into managed services agreements (“MSAs”) with professional medical services companies that provide health care services to patients. The medical services companies pay XpresTest a monthly fee to operate in the XpresCheck Wellness Centers. Under the terms of MSAs, the Company provides office space, equipment, supplies, non-licensed staff, and management services in return for a management fee. Effective July 1, 2021, the Company determined that the PLLCs are VIEs due to their equity holders having insufficient capital at risk, and the Company having a variable interest and a primary beneficiary in the PLLCs.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin-bottom:8pt;text-decoration-color:#000000;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While management has used all currently available information in assessing the Company’s business prospects, the ultimate impact of the COVID-19 pandemic and its XpresCheck Wellness Centers on its results of operations, financial condition and cash flows remains uncertain. The success or failure of the Company’s XpresCheck Wellness Centers could also have a material effect on the Company’s business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:none;">XpresCheck Wellness Centers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">XpresCheck’s business has management services agreements with state licensed physicians and nurse practitioners, under which we administer COVID-19 testing options, including a Polymerase Chain Reaction (PCR) test and a rapid PCR test. As of the date of this report, there are 15 operating XpresCheck locations operating in 12 airports, including following locations opened since December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On January 12, 2021, the Company opened its second XpresCheck Wellness Center at Boston’s Logan International Airport. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seven</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On January 20, 2021, the Company announced the opening of an XpresCheck Wellness Center at Salt Lake City International Airport. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">On February 16, 2021, the Company announced the opening of our second XpresCheck Wellness Center facility at Newark Liberty International Airport. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On March 8, 2021, the Company announced the opening of an XpresCheck Wellness Center at Houston George Bush Intercontinental Airport. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On March 15, 2021, the Company announced the opening of XpresCheck Wellness Centers at Dulles International and Reagan National Airports in Virginia, containing </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nine</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> separate testing rooms, respectively, to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On April 8, 2021, the Company announced the opening of an XpresCheck Wellness Center at Seattle-Tacoma International Airport. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eight</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">On April 21, 2021, the Company announced the opening of an XpresCheck Wellness Center at San Francisco International Airport. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nine</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On October 13, 2021, the Company opened an XpresCheck Wellness Center at Hartsfield-Jackson Atlanta International Airport (ATL) Concourse E, converting a legacy XpresSpa located in Concourse E. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"> In February 2022, a second XpresCheck Wellness Center opened at Denver International Airport, pre-security in the Great Hall. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">In March 2022, the Company opened an XpresCheck Wellness Center in Orlando International Airport, pre-security, in the South Walk area of the Main Terminal. It contains </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> separate testing rooms to provide diagnostic COVID-19 testing.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2021, XpresCheck initiated a $2,001 eight-week pilot program with the Centers for Disease Control and Prevention (CDC) in collaboration with Concentric by Ginkgo. Under this program, XpresCheck is conducting biosurveillance monitoring at four major U.S. airports (JFK International Airport, Newark Liberty International Airport, San Francisco International Airport, and Hartsfield-Jackson Atlanta International Airport) aimed at identifying existing and new SARS-CoV-2 variants. On January 31, 2022, the Company announced the extension of the program, bringing the total contract to $5,534. Approximately $1,557 of the original $2,001 in revenue was recognized during the fourth quarter of 2021. We anticipate the remaining $3,977 of the full $5,534 amount will be realized in the first and second quarters of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:none;">XpresSpa Premium Spa Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There are currently sixteen operating XpresSpa domestic locations (including the Company’s franchise location in Austin-Bergstrom International Airport) and the Company expects to re-open four additional domestic locations in the near-term. A majority of the domestic XpresSpa locations are operating approximately eight hours per day during the busiest hours (compared to up to sixteen hours per day pre-pandemic). Additionally, XpresSpa implemented a price increase in mid-October 2021 in its efforts to return to profitability. And as airport volumes improve, the Company will continue to review operating hours to optimize revenue opportunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the fourth quarter, the Company began testing several new services to take advantage of a growing interest in non-traditional spa services and expansion of our retail offering to align more closely with the services we provide. The </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Company is evaluating the success of these new initiatives at each airport on an on-going basis and will incorporate changes to our approach as more of the portfolio is reactivated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">There are also six international locations operating, including three XpresSpa locations in Dubai International Airport in the United Arab Emirates and three XpresSpa locations in Schiphol Amsterdam Airport in the Netherlands. The Company has also signed for five locations at Istanbul Airport and expect to open the first store this summer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Treat</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Treat is the Company’s new travel, health and wellness brand transforming the way one accesses care through a suite of health and wellness services supported by an integrated digital platform and a relevant retail offering to the traveling public.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Treat’s on-site centers (currently located in JFK International Airport and opening soon in Phoenix Sky Harbor International Airport and later this year in Salt Lake City International Airport) provide access to health and wellness services for travelers. The Company’s teams provide travel-related diagnostic testing for virus, cold, flu and other illnesses as well as hydration therapy, IV Drips, and vitamin injections. Travelers can purchase time blocks to use the Company’s wellness rooms to engage in interactive services like self-guided yoga, meditation and low impact weight exercises or to relax and unplug from the hectic pace of the airport and renew themselves before or after their trip.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Treat offers a website (www.treat.com) and mobile app to complement the offering with relevant health and wellness content designed to help people on the go with information that could impact their travel. The platform provides travelers access to a comprehensive online marketplace of services including global illness tracker tools such as the COVID-19 Requirements Map, on-demand chat care by licensed providers, a health wallet to store personal and family health records (including COVID-19 testing results), and a scheduler to arrange for direct care at one of our on-site locations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had approximately $105,506 of cash and cash equivalents, and total current assets of approximately $108,979. The Company's total current liabilities balance, which includes accounts payable, deferred revenue, accrued expenses, and the current portions of its promissory note and operating lease liabilities was approximately $19,827 as of December 31, 2021. The working capital was $89,152 as of December 31, 2021, compared to a working capital of $78,302 as of December 31, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has aggressively reduced operating and overhead expenses in the XpresSpa brand, while it continues to focus on its overall profitability, resulting in generation of positive cash flows from operations, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has taken actions to improve its overall cash position and access to liquidity through equity offerings and debt retirements, by exploring valuable strategic partnerships, right sizing its corporate structure and streamlining its operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2021, holders of our December 2020 Investor Warrants, December 2020 Placement Agent Warrants and December 2020 Placement Agent Tail Fee Warrants exercised a total of 11,273,529 warrants for shares of our common stock. We received gross proceeds of approximately $19,245. In accordance with our placement agent agreements with H.C. Wainwright & Co., LLC and Palladium, we paid cash fees of $2,162 and issued 846,588 warrants to H.C. Wainwright & Co., LLC at an exercise price of $2.125 per share and 325,500 warrants to Palladium at an exercise price of $1.70 per share. See <i style="font-style:italic;">Note 12. Stockholders’ Equity</i> for related discussion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:none;">Airport Rent Concessions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has received rent concessions from landlords on a majority of its leases, allowing for the relief of minimum guaranteed payments in exchange for percentage-of-revenue rent or providing relief from rent through payment deferrals. Currently, the period of relief from these payments range from <span style="-sec-ix-hidden:Hidden_C2qgPPR23kyObOoAvL7GTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span>-to twenty eight-months and began in March 2020. The Company received minimum guaranteed payment concession of approximately $2,078 and $2,107, respectively, in years ended December 31, 2021 and 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;"></span></p>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3
CY2021	xspa	Revenue Contract Amount Not Yet Recognized RevenueContractAmountNotYetRecognized	2001000
CY2022Q1	xspa	Revenue Contract Amount Not Yet Recognized RevenueContractAmountNotYetRecognized	5534000
CY2021Q4	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	1557000
CY2021	xspa	Revenue Contract Amount Not Yet Recognized RevenueContractAmountNotYetRecognized	2001000
CY2022Q1	xspa	Revenue Contract Amount Not Yet Recognized RevenueContractAmountNotYetRecognized	5534000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	105506000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	108979000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19827000
CY2021Q4	xspa	Working Capital WorkingCapital	89152000
CY2020Q4	xspa	Working Capital Deficiency WorkingCapitalDeficiency	78302000
CY2021	xspa	Lease Concessions LeaseConcessions	2078000
CY2020	xspa	Lease Concessions LeaseConcessions	2107000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">(b) Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from such estimates. Significant items subject to such estimates and assumptions include the Company’s long-lived assets, intangibles assets, the useful lives of the Company’s intangible assets, the valuation of the Company’s derivative warrant liabilities, the valuation of stock-based compensation, deferred tax assets and liabilities, income tax uncertainties, and other contingencies.</p>
CY2021	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">(e) Derivative instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes all derivative instruments as either assets or liabilities in the consolidated balance sheets at their respective fair values. The Company’s derivative instruments are revalued at each reporting date, with changes in the fair value of the instruments included in the consolidated statements of operations and comprehensive loss as non-operating income (expense). The Company reviews the terms of features embedded in non-derivative instruments to determine if such features require bifurcation and separate accounting as derivative financial instruments. Equity-linked derivative instruments are evaluated in accordance with FASB Accounting Standard Codification (“ASC”) 815-40, “<i style="font-style:italic;">Contracts in an Entity’s Own Equity,”</i> to determine if such instruments are indexed to the Company’s own stock and qualify for classification in equity.</p>
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	3934000
CY2021Q4	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	1557000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.05
CY2021	xspa	Net Loss Attributable To Common Shareholders NetLossAttributableToCommonShareholders	3349000
CY2020	xspa	Net Loss Attributable To Common Shareholders NetLossAttributableToCommonShareholders	-91433000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105076758
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44567542
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2826871
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.57
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">(y) Reclassification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certain balances in the 2020 consolidated financial statements have been reclassified to conform to the presentation in the 2021 consolidated financial statements, primarily the classification and presentation of deferred revenue. Such reclassifications did not have a material impact on the consolidated financial statements.</p>
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	3349000
CY2020	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-90488000
CY2020	xspa	Deemed Dividend On Series D Warrants DeemedDividendOnSeriesDWarrants	945000
CY2021	xspa	Net Loss Attributable To Common Shareholders NetLossAttributableToCommonShareholders	3349000
CY2020	xspa	Net Loss Attributable To Common Shareholders NetLossAttributableToCommonShareholders	-91433000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104306173
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44567542
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.05
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	40473979
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	49398269
CY2021Q4	us-gaap	Credit And Debit Card Receivables At Carrying Value CreditAndDebitCardReceivablesAtCarryingValue	813000
CY2020Q4	us-gaap	Credit And Debit Card Receivables At Carrying Value CreditAndDebitCardReceivablesAtCarryingValue	7000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106257000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90502000
CY2021Q4	us-gaap	Cash Cash	102560000
CY2020Q4	us-gaap	Cash Cash	88636000
CY2021Q4	xspa	Currency Other Than Us Dollars CurrencyOtherThanUsDollars	2133000
CY2020Q4	xspa	Currency Other Than Us Dollars CurrencyOtherThanUsDollars	1158000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	751000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	701000
CY2021Q4	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	103339000
CY2020Q4	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	88556000
CY2021Q4	xspa	Cash Held In Overseas Accounts CashHeldInOverseasAccounts	2113000
CY2020Q4	xspa	Cash Held In Overseas Accounts CashHeldInOverseasAccounts	1158000
CY2020	us-gaap	Depreciation Depreciation	2853000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1047000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1135000
CY2021Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	48000
CY2020Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	186000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1095000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1321000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13398000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9107000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6740000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4946000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6658000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4161000
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	90000
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4954000
CY2021	us-gaap	Depreciation Depreciation	2754000
CY2021Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	722000
CY2020Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1768000
CY2021Q4	us-gaap	Leveraged Lease Investment LeveragedLeaseInvestment	2030000
CY2020Q4	us-gaap	Leveraged Lease Investment LeveragedLeaseInvestment	736000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2810000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2588000
CY2021Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	58000
CY2020Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	85000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1074000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	23000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	17000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3732000
CY2021Q4	us-gaap	Leveraged Lease Investment LeveragedLeaseInvestment	2030000
CY2020Q4	us-gaap	Leveraged Lease Investment LeveragedLeaseInvestment	736000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5341000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1609000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3732000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2033000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1163000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	870000
CY2021	xspa	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	447000
CY2020	xspa	Amortization And Impairment Of Intangible Assets AmortizationAndImpairmentOfIntangibleAssets	2357000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1476000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1142000
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.1124
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.090
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	4230000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	2344000
CY2021	xspa	Right Of Use Asset Obtained In Exchange For New And Modified Operating Lease Liability RightOfUseAssetObtainedInExchangeForNewAndModifiedOperatingLeaseLiability	-3646000
CY2020	xspa	Right Of Use Asset Obtained In Exchange For New And Modified Operating Lease Liability RightOfUseAssetObtainedInExchangeForNewAndModifiedOperatingLeaseLiability	-3144000
CY2021	xspa	Right Of Use Asset Surrendered In Exchange For Termination Of Operating Lease Liability RightOfUseAssetSurrenderedInExchangeForTerminationOfOperatingLeaseLiability	9000
CY2020	xspa	Right Of Use Asset Surrendered In Exchange For Termination Of Operating Lease Liability RightOfUseAssetSurrenderedInExchangeForTerminationOfOperatingLeaseLiability	11000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3506000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3071000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2545000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1760000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	718000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	808000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	12408000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2168000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10240000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M9D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1006
CY2021	us-gaap	Variable Lease Payment VariableLeasePayment	576000
CY2020	us-gaap	Variable Lease Payment VariableLeasePayment	611000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	2069000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	2057000
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	747000
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	6341000
CY2020Q4	us-gaap	Unsecured Long Term Debt UnsecuredLongTermDebt	2355000
CY2021Q4	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	3584000
CY2020Q4	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	3298000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	3584000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	5653000
CY2020Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1.5
CY2020Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1942131
CY2020Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	2913197
CY2020Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1.5
CY2020Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1374750
CY2020Q2	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	2062126
CY2020Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6511280
CY2020Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	4258000
CY2020Q1	xspa	Equity Offering Costs EquityOfferingCosts	626000
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.70
CY2021Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	510460
CY2020Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.68
CY2020Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.525
CY2020	xspa	Deemed Dividend Reduction In Exercise Price DeemedDividendReductionInExercisePrice	140000
CY2020	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	1221945
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2856000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1328000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1353888
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.82
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1668297
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.56
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8334
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.53
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	183230
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	1.61
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	3750
CY2021	xspa	Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expired Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpiredWeightedAverageGrantDateFairValue	50.8
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1024694
CY2021	xspa	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageGrantDateFairValue	3.81
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M15D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y6M
CY2021Q4	xspa	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Vested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndVestedIntrinsicValue	545000
CY2020Q4	xspa	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Vested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndVestedIntrinsicValue	0
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3
CY2021Q4	xspa	Number Of Locations Operated NumberOfLocationsOperated	2
CY2021	us-gaap	Revenues Revenues	73729000
CY2020	us-gaap	Revenues Revenues	8385000
CY2021Q4	xspa	Long Lived Assets LongLivedAssets	14497000
CY2020Q4	xspa	Long Lived Assets LongLivedAssets	10399000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3
CY2021	us-gaap	Revenues Revenues	73729000
CY2020	us-gaap	Revenues Revenues	8385000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	4107000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-40104000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3201000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5210000
CY2021Q4	xspa	Property Plant Equipment Capital Expenditure PropertyPlantEquipmentCapitalExpenditure	8671000
CY2020Q4	xspa	Property Plant Equipment Capital Expenditure PropertyPlantEquipmentCapitalExpenditure	4349000
CY2021Q4	xspa	Long Lived Assets LongLivedAssets	14497000
CY2020Q4	xspa	Long Lived Assets LongLivedAssets	10399000
CY2021Q4	us-gaap	Assets Assets	127266000
CY2020Q4	us-gaap	Assets Assets	103133000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5966000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2440000
CY2021Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	845000
CY2020Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	2221000
CY2021Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	2862000
CY2020Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	287000
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	603000
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	551000
CY2021Q4	xspa	Accrued Liability For Unredeemed Gift Cards AccruedLiabilityForUnredeemedGiftCards	494000
CY2020Q4	xspa	Accrued Liability For Unredeemed Gift Cards AccruedLiabilityForUnredeemedGiftCards	495000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	3137000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-91030000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-188000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1195000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2949000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92225000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	930000
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	347000
CY2021Q4	xspa	Credit Card Processing Fees CreditCardProcessingFees	501000
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	757000
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	127000
CY2021Q4	xspa	Accounts Payable Accrued Liabilities And Other Current AccountsPayableAccruedLiabilitiesAndOtherCurrent	12958000
CY2020Q4	xspa	Accounts Payable Accrued Liabilities And Other Current AccountsPayableAccruedLiabilitiesAndOtherCurrent	6468000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	507000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	56000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	56000
CY2020	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	7000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2949000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92225000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	xspa	Effective Income Tax Rate Reconciliation Tax Credits And Adjustments Other Amount EffectiveIncomeTaxRateReconciliationTaxCreditsAndAdjustmentsOtherAmount	-619000
CY2020	xspa	Effective Income Tax Rate Reconciliation Tax Credits And Adjustments Other Amount EffectiveIncomeTaxRateReconciliationTaxCreditsAndAdjustmentsOtherAmount	19367000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1516000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2395000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-10946000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	12459000
CY2021	xspa	Effective Income Tax Rate Reconciliation Nondeductible Expense Expiration Of Stock Options Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExpirationOfStockOptionsAmount	4445000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1104000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	10841000
CY2021	xspa	Effective Income Tax Rate Reconciliation Nondeductible Expense Return To Provision Adjustment Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionAdjustmentAmount	2403000
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	915000
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-1531000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	56000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	48556000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	50446000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4765000
CY2021Q4	xspa	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Intangible Assets DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIntangibleAssets	4235000
CY2020Q4	xspa	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Intangible Assets DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIntangibleAssets	9034000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	53298000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	64245000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	53298000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	64245000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	53298000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	51788000
CY2020Q4	xspa	Deferred Tax Assets Return To Provision Trueup DeferredTaxAssetsReturnToProvisionTrueup	-473000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	64245000
CY2021Q4	xspa	Deferred Tax Assets Return To Provision Trueup DeferredTaxAssetsReturnToProvisionTrueup	2403000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	53298000
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	150926000
CY2021	xspa	Net Operating Loss Expiration NetOperatingLossExpiration	P20Y
CY2021Q4	xspa	Operating Loss Carry Forwards Without Limitation OperatingLossCarryForwardsWithoutLimitation	56336000
CY2021	xspa	Number Of Individuals Joined Case NumberOfIndividualsJoinedCase	415

Files In Submission

Name	View Source	Status
0001558370-22-004897-index-headers.html	Edgar Link	pending
0001558370-22-004897-index.html	Edgar Link	pending
0001558370-22-004897.txt	Edgar Link	pending
0001558370-22-004897-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xspa-20211231.xsd	Edgar Link	pending
xspa-20211231x10k.htm	Edgar Link	pending
xspa-20211231x10k_htm.xml	Edgar Link	completed
xspa-20211231xex10d48.htm	Edgar Link	pending
xspa-20211231xex21.htm	Edgar Link	pending
xspa-20211231xex23d1.htm	Edgar Link	pending
xspa-20211231xex31d1.htm	Edgar Link	pending
xspa-20211231xex31d2.htm	Edgar Link	pending
xspa-20211231xex32.htm	Edgar Link	pending
xspa-20211231_cal.xml	Edgar Link	unprocessable
xspa-20211231_def.xml	Edgar Link	unprocessable
xspa-20211231_lab.xml	Edgar Link	unprocessable
xspa-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XWEL
XWELL Inc Stock $xwel

2021 Q4 Form 10-K Financial Statement

#000155837022004897 Filed on March 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XWEL XWELL Inc Stock $xwel

2021 Q4 Form 10-K Financial Statement

#000155837022004897 Filed on March 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XWEL
XWELL Inc Stock $xwel